Buscar

 Detalle_Publicacion

Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanoma

Abstract: Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91-99 peptide (GNP-LLO91-99), which acts as a novel adjuvant for cancer therapy. GNP-LLO91-99, when used to vaccinate mice, exhibited dual antitumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients. GNP-LLO91-99 nanoparticles caused tumour apoptosis and induced antigen- and melanoma-specific cytotoxic Th1 responses (P ? 0.5). We propose this adjuvant nanotherapy for preventing the progression of the first stages of melanoma.

 Fuente: Nanoscale. 2017 Aug 3;9(30):10721-10732

Editorial: Royal Society of Chemistry

 Año de publicación: 2017

Nº de páginas: 12

Tipo de publicación: Artículo de Revista

DOI: 10.1039/c7nr02494k

ISSN: 2040-3364,2040-3372

Proyecto español: SAF2012-34203

Autores/as

RICARDO CALDERON GONZALEZ

HECTOR TERAN NAVARRO

GARCÍA, I.

MARRADI, M.

SALCINES CUEVAS, D.

SONSOLES JUANA YAÑEZ DIAZ

SOLIS ANGULO, A.

ELISABET FRANDE CABANES

MARIA DE LA ALMUDENA GARCIA CASTAÑO

FERNANDO RIVERA HERRERO

FREIRE, J.

CARMEN ALVAREZ DOMINGUEZ